National Institute on Aging; Notice of Closed Meeting, 71079 [2020-24615]

Download as PDF 71079 Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices Agenda: To review and evaluate grant applications. Place: Video Assisted Meeting. Contact Person: Leonid V. Tsap, Ph.D., Scientific Review Officer, Extramural Programs, National Library of Medicine, NIH, 6705 Rockledge Drive, Suite 500, Bethesda, MD 20892–7968, 301–827–7077, tsapl@ mail.nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS) Dated: November 2, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–24669 Filed 11–5–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Clinical trials for COVID 19 management in older individuals. Date: December 11, 2020. Time: 10:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Gateway Building, Suite 2W200, Bethesda, MD 20892, (301) 496–9374, grimaldim2@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: November 2, 2020. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–24615 Filed 11–5–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES SUMMARY: The National Heart, Lung and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), both of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive patent license to Inversago Pharma Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice. Only written comments and/or applications for a license which are received by the National Human Genome Research Institute’s Technology Transfer Office on or before November 23, 2020 will be considered. DATES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Anna Solowiej, Ph.D., J.D., Senior Licensing and Patenting Manager, NHGRI Technology Transfer Office; Telephone (301) 435–7791; Email: anna.solowiej@nih.gov. ADDRESSES: The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma Inc.: Prospective Grant of Exclusive Patent License: Treatment of HermanskyPudlak Syndrome and Idiopathic Pulmonary Fibrosis National Institutes of Health, HHS. NIH ref No. Patent No. or application No. Issue date Filing date E–282–2012–0–US–01 .......... E–282–2012–0–PCT–02 ........ E–282–2012–0–US–03 .......... E–282–2012–0–CA–04 .......... E–282–2012–0–EP–05 .......... E–282–2012–0–CH–12 .......... E–282–2012–0–DE–13 .......... E–282–2012–0–FR–14 .......... E–282–2012–0–GB–15 .......... E–282–2012–0–IE–16 ........... E–282–2012–0–IN–06 ........... E–282–2012–0–JP–07 ........... E–282–2012–0–CN–08 .......... E–282–2012–0–US–09 .......... E–282–2012–0–US–10 .......... E–282–2012–0–US–11 .......... E–282–2012–1–US–01 .......... E–282–2012–1–PCT–02 ........ E–282–2012–1–EP–05 .......... E–282–2012–1–US–08 .......... E–282–2012–1–US–09 .......... E–282–2012–2–US–01 .......... E–282–2012–2–PCT–02 ........ E–282–2012–2–CN–03 .......... E–282–2012–2–EP–04 .......... E–140–2014–0–US–01 .......... E–140–2014–0–PCT–02 ........ E–140–2014–0–AU–03 .......... E–140–2014–0–CA–04 .......... E–140–2014–0–CN–05 .......... 61/725,949 .................... PCT/US2013/069686 ... 9,765,031 ...................... 2889697 ........................ 13802153.0 ................... 13802153.0 ................... 13802153.0 ................... 13802153.0 ................... 13802153.0 ................... 13802153.0 ................... 3733/DELNP/2015 ........ 6272626 ........................ ZL201380069389.9 ...... 10,683,270 .................... 15/674,333 .................... 16/870,093 .................... 62/171,179 .................... PCT/US2016/035291 ... 16728547.7 ................... 15/579,123 .................... 16/438,850 .................... 15/061,829 .................... PCT/US2017/020250 ... 2017800118698 ............ 17711443.6 ................... 61/991,333 .................... PCT/US2015/029946 ... 2015255765 .................. 2948349 ........................ 201580028788.X .......... ............................................... ............................................... September 19, 2017 ............ ............................................... TBD ...................................... TBD ...................................... TBD ...................................... TBD ...................................... TBD ...................................... TBD ...................................... ............................................... January 12, 2018 ................. August 20, 2019 ................... June 16, 2020 ...................... TBD (application allowed) .... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... ............................................... February 7, 2020 .................. November 13, 2012 ...... November 12, 2013 ...... November 12, 2013 ...... April 27, 2015 ............... June 01, 2015 .............. November 12, 2013 ...... November 12, 2013 ...... November 12, 2013 ...... November 12, 2013 ...... November 12, 2013 ...... May 1, 2015 ................. May 11, 2015 ............... July 3, 2015 .................. August 10, 2017 ........... August 10, 2017 ........... May 8, 2020 ................. June 4, 2015 ................ June 1, 2016 ................ June 1, 2016 ................ December 1, 2017 ........ June 12, 2019 .............. March 4, 2016 .............. March 1, 2017 .............. March 1, 2017 .............. March 1, 2017 .............. May 9, 2014 ................. May 8, 2015 ................. November 7, 2016 ........ May 8, 2015 ................. May 8, 2015 ................. VerDate Sep<11>2014 19:00 Nov 05, 2020 Jkt 253001 Notice. SUPPLEMENTARY INFORMATION: National Institutes of Health AGENCY: ACTION: PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 Title Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid Cannabinoid E:\FR\FM\06NON1.SGM 06NON1 Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Mediating Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds. Compounds.

Agencies

[Federal Register Volume 85, Number 216 (Friday, November 6, 2020)]
[Notices]
[Page 71079]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24615]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; Clinical trials for COVID 19 management in older individuals.
    Date: December 11, 2020.
    Time: 10:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Maurizio Grimaldi, MD, Ph.D., Scientific Review 
Officer, Scientific Review Branch, National Institute on Aging, 
National Institutes of Health, 7201 Wisconsin Avenue, Gateway 
Building, Suite 2W200, Bethesda, MD 20892, (301) 496-9374, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)

    Dated: November 2, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-24615 Filed 11-5-20; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.